Back to News
Market Impact: 0.35
Gilead's Bixlenvo Gets FDA Approval For Virologically Suppressed Adults With HIV
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
Gilead Sciences (GILD) said the U.S. FDA approved Bixlenvo (bictegravir/lenacapavir) as a once-daily single-tablet regimen for HIV treatment in virologically suppressed adults. The approval is a meaningful regulatory win that could support growth expectations for the franchise.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.65
Ticker Sentiment
GILD0.70
More News
- Which Pharmaceuticals ETF Is the Better Buy: iShares’ IHE or Invesco’s PJP?
- Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH?
- ‘If nothing is done, it’s almost inevitable’: Ukraine’s Yuriy Ryzhenkov on why steelmaking is on the brink of collapse as Russian bombing intensifies
- Why is LG Innotek stock plunging today?
- TotalEnergies, KKR expand U.S. solar venture with 700 MW addition
- TikTok CEO sees major scientific breakthroughs from AI within three years